Korro Bio, Inc.

Korro Bio is a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA. By leveraging its proprietary Oligonucleotide Promoted Editing of RNA (OPERA) platform, the company aims to discover and develop therapies for rare and highly prevalent diseases. Korro Bio harnesses the body's natural RNA editing machinery to make precise, single-base edits, addressing the underlying genetic causes of debilitating conditions.